7月17日，昭衍新药盘中下跌5.65%，报23.32港元，成交额1.8亿港元。
消息面上，公司于7月16日晚间发布股票交易异常波动公告，明确提示"存在市场情绪过热、非理性炒作风险，股价随时可能下跌"，并指出生物资产公允价值受多种不确定性因素影响，存在较大价值波动风险。此前三个交易日股价累计涨幅超20%，龙虎榜数据显示一机构席位三日累计卖出约5.61亿元。市场对公司营收仅微增0%-10.5%、利润高度依赖实验猴公允价值变动而非核心安评主业改善的盈利模式可持续性存疑，抛压延续。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.